Antengene initiates phase 1 trial of ATG-201 for autoimmune conditions
Antengene Corporation has administered the first dose of ATG-201 in a Phase I trial designed to evaluate the drug's safety and efficacy in treating B cell-mediated autoimmune diseases.
Antengene Corporation, a Shanghai-based biotechnology firm, has launched the ATTRACT Phase I clinical study. The trial marks the first human administration of ATG-201, a CD19 x CD3 T-cell engager (TCE) candidate designed to address autoimmune disorders driven by B-cell activity.
The ATTRACT study aims to assess the drug's safety, tolerability, and pharmacokinetics in patients. By targeting CD19, a protein found on the surface of B cells, the therapeutic seeks to deplete pathogenic B cells, a mechanism increasingly explored in the treatment of systemic autoimmune conditions.
This trial represents a shift in focus for Antengene, which has traditionally concentrated on oncology treatments. The move into autoimmune disease therapy reflects broader industry trends where oncology platforms are being repurposed to address inflammatory and autoimmune conditions.
The company will monitor initial participants to determine the optimal dosage and safety profile before expanding the study. Further data regarding the drug's performance will be released as the trial progresses.